中生製藥(01177.HK)旗下輔助生殖領域降調藥獲內地通過一致性評價
中生製藥(01177.HK)公布,集團的輔助生殖領域降調藥「醋酸加尼瑞克注射液」(商品名:晴樂)已獲得中國國家藥品監督管理局頒發藥品補充申請批准通知書,通過了仿製藥質量和療效一致性評價,為同品
種國內首家通過一致性評價。
目前國內市場僅本集團及原研藥生產商兩家企業擁有醋酸加尼瑞克注射液生產批文。晴樂通過了一致性評價,可成為原研藥的替代產品,為不孕症患者提供多一種用藥選擇,減輕不孕症患者承受著心理和經濟上的雙重負擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.